Thymic carcinoma surgery: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Thymic carcinoma}} | {{Thymic carcinoma}} | ||
{{CMG}}; {{AE}} {{ | {{CMG}}; {{AE}} {{PSD}} | ||
==Overview== | ==Overview== | ||
Surgery is the mainstay of treatment for thymic carcinoma. | |||
==Surgery== | ==Surgery== | ||
Treatment options for thymic carcinoma include the following: | Treatment options for thymic carcinoma include the following: |
Revision as of 16:15, 4 January 2016
Thymic Carcinoma Microchapters |
Diagnosis |
---|
Case Studies |
Thymic carcinoma surgery On the Web |
American Roentgen Ray Society Images of Thymic carcinoma surgery |
Risk calculators and risk factors for Thymic carcinoma surgery |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]
Overview
Surgery is the mainstay of treatment for thymic carcinoma.
Surgery
Treatment options for thymic carcinoma include the following:
- Surgery
- Radiation
- Cisplatin-based chemotherapy
- For patients with clinically resectable disease, surgical resection is often the initial therapeutic intervention.
- For clinically borderline or frankly unresectable lesions, neoadjuvant (preoperative) chemotherapy or thoracic radiation therapy, or both, is given.
- Patients presenting with locally advanced disease should be carefully evaluated and undergo multimodality therapy.
- Patients with poor performance status and high associated operative risks are generally not considered for these types of aggressive treatments.
- Patients with metastatic disease may respond to combination chemotherapy.